The answer to this is more complicated than one might think and centers around the question of the strength and longevity of the immune response.
According to the research that tested over 70,000 people in Israel's four major health funds, the percentage of infected people in Israel is somewhere between one and three percent of the population.
The vaccine stands out because recent results show that it's effective with treating healthy patients and offers "double layered," long-term protection against the virus.
“Antibodies don’t mean you have immunity. [A test] doesn’t say if you have enough of the right number of antibodies or how long they live."